Yang et al.‘s research suggested that in early breast cancer, patients with HER2-low expression had a more favorable prognosis than those with HER2-0 expression breast cancer, regardless of hormone receptor status [36]. This evidence concerns the gene ERBB2 and breast carcinoma.